<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02642471</url>
  </required_header>
  <id_info>
    <org_study_id>2015-FXY-073</org_study_id>
    <nct_id>NCT02642471</nct_id>
  </id_info>
  <brief_title>Sentinel Lymph Node Biopsy Versus Systematic Pelvic Lymphadenectomy in Early-stage Cervical Cancer</brief_title>
  <official_title>Application of Sentinel Lymph Node Biopsy (SLNB) in Early-stage Cervical Cancer: A Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The diagnostic value of sentinel lymph node biopsy in early-stage cervical cancer has been
      well studied. However, there were no randomized controlled study on comparing the long-term
      outcomes of sentinel lymph node biopsy and conventional procedure. The investigators perform
      a phase III, randomized controlled trial to determine whether pelvic lymphadenectomy could be
      replaced by sentinel lymph node biopsy in surgical treatment for patients with early-stage
      cervical cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study comprises two parts: Part I: To compare the outcomes of managements with and
      without pelvic lymphadenectomy for patients with negative sentinel lymph node; Part II: To
      compare the outcomes of managements with and without pelvic lymphadenectomy for patients with
      positive sentinel lymph node. Patients with newly diagnosed International Federation of
      Gynecology and Obstetrics (FIGO) stage IA2, IB1 and IIA1 cervical cancer are eligible for our
      study. The tumor diameter should be less than 3cm. Sentinel lymph node biopsy will be
      performed at the beginning of operations. After pathological examination of frozen section,
      patients will be assigned to Part I or Part II study according to their status of sentinel
      nodes. In both parts of this trail, patients have equal chance to be randomly assigned to
      experimental arms (undergo radical hysterectomy plus systematic pelvic lymphadenectomy) and
      controlled arms (undergo radical hysterectomy only). Postoperative pelvic radiotherapy will
      be started within 6 weeks after surgery if the patients have pelvic lymph node metastasis,
      parametrial involvement, deep stromal invasion or positive margin. Extended-field external
      beam therapy, delivering a dose of 4500cGy by a four-field technique, will be administered to
      patients with positive para-aortic nodes. High-dose rate brachytherapy will be delivered to
      the vaginal stump if patients have positive surgical margins. The primary end point is
      2-years progression-free survival. The secondary end points are overall survival, long-term
      outcome of sentinel lymph node biopsy and the quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrence of retroperitoneal lymph nodes</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>long-term outcome of sentinel lymph node biopsy</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Surgery</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with negative sentinel nodes confirmed by pathological examination of frozen section will be randomly assigned to Arm 1 or Arm 2 Arm 1: patients undergo radical hysterectomy±salpingo-oophorectomy (no systematic pelvic lymphadenectomy) Arm 2: patients undergo radical hysterectomy±salpingo-oophorectomy+pelvic lymph node dissection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients with negative sentinel nodes confirmed by pathological examination of frozen section will be randomly assigned to Arm 1 or Arm 2 Arm 1: patients undergo radical hysterectomy±salpingo-oophorectomy (no systematic pelvic lymphadenectomy) Arm 2: patients undergo radical hysterectomy±salpingo-oophorectomy+pelvic lymph node dissection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with positive sentinel nodes confirmed by pathological examination of frozen section will be randomly assigned to Arm 3 or Arm 4 Arm 3: patients undergo radical hysterectomy±salpingo-oophorectomy (no systematic pelvic lymphadenectomy) Arm 4: patients undergo radical hysterectomy±salpingo-oophorectomy+pelvic lymph node dissection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients with positive sentinel nodes confirmed by pathological examination of frozen section will be randomly assigned to Arm 3 or Arm 4 Arm 3: patients undergo radical hysterectomy±salpingo-oophorectomy (no systematic pelvic lymphadenectomy) Arm 4: patients undergo radical hysterectomy±salpingo-oophorectomy+pelvic lymph node dissection</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>no systematic pelvic lymphadenectomy</intervention_name>
    <description>systematic pelvic lymphadenectomy is omitted in surgical treatment</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with newly histologically confirmed cervical carcinoma

          -  Histopathology squamous carcinoma, adenocarcinoma or adeno-squamous carcinoma

          -  Original clinical stage must be IA2, IB1 or IIA1 （FIGO)

          -  Age between 18-65

          -  Patients must give signed informed consent

          -  P.S status: 0-1

          -  Estimated survival time ＞ 3 months

          -  Tumor diameter ≤ 3 cm

        Exclusion Criteria:

          -  The presence of uncontrolled life-threatening illness

          -  Receiving other ways of anti-cancer therapy

          -  Investigator consider the patients can't finish the whole study

          -  With normal liver function test (ALT、AST&gt;2.5×ULN)

          -  With normal renal function test (Creatinine&gt;1.5×ULN)

          -  WBC&lt;4,000/mm3 or PLT&lt;100,000/mm
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jihong Liu, Ph. D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jihong Liu, Ph. D</last_name>
    <phone>86-20-87343102</phone>
    <email>liujih@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hua Tu, Ph. D</last_name>
    <phone>86-20-87343014</phone>
    <email>tuhua@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jihong Liu, Ph.D.</last_name>
      <phone>86-20-87343102</phone>
      <email>liujih@mail.sysu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Hua Tu, Ph.D.</last_name>
      <phone>86-20-87343104</phone>
      <email>tuhua@sysucc.org.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 24, 2015</study_first_submitted>
  <study_first_submitted_qc>December 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2015</study_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Jihong Liu</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>sentinel lymph node</keyword>
  <keyword>pelvic lymphadenectomy</keyword>
  <keyword>cervical carcinoma</keyword>
  <keyword>surgery</keyword>
  <keyword>radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

